SCHEMBL394471

SCHEMBL394471

Cc1c(C(=O)O)c(C)n(C(C(N)=O)N2CCCC2)c1C=C1C(=O)Nc2c(Nc3cccc(NC(=O)c4ccccc4)c3)cccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 3/20 0.40
▸ SIRT2 Q8IXJ6 1/20 0.38
▸ NTRK3 Q16288 1/20 0.37
▸ TLK2 Q86UE8 3/20 0.36
▸ PSD A5PKW4 1/20 0.36
▸ TP53 P04637 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ FLT4 P35916 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ MAPK14 Q16539 4/20 0.34
▸ GSK3B P49841 3/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ APAF1 O14727 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396154 0.93 MAPK14 (0.39) NTRK1TLK2TP53SMN1; SMN2JAK3
SCHEMBL394153 0.90 RET (0.45) NTRK1NTRK3RAB9AKDRFLT3
SCHEMBL393773 0.88 TLK2 (0.48) NTRK1NTRK3TLK2JAK3KIT
SCHEMBL398246 0.88 NTRK1 (0.53) NTRK1NTRK3TLK2KITFLT4
SCHEMBL394537 0.88 NTRK1 (0.52) NTRK1NTRK3TLK2KITFLT4
SCHEMBL396423 0.86 FLT3 (0.51) NTRK1NTRK3TLK2KITFLT4
SCHEMBL396420 0.85 MAPK14 (0.45) NTRK1NTRK3TLK2KITFLT4
SCHEMBL396166 0.85 TLK2 (0.47) NTRK1TLK2JAK3MAPK14GSK3B
SCHEMBL395533 0.85 FLT3 (0.48) NTRK1TLK2JAK3KITFLT4
SCHEMBL396429 0.85 NTRK1 (0.40) NTRK1SIRT2NTRK3TLK2PSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback